Tildus Therapeutics July 2021 Investor Presentation

Clinical-stage biotech company developing HADUVIO, an oral dual-acting therapeutic targeting pruritus (itching) and cough through peripheral and central kappa/mu receptor modulation. Presents data from Phase 2 trials in uremic pruritus and prurigo nodolaris, with lead candidates in large-market indications including IPF.